Form 4: Herbalife CCO Granted 15,182 Stock Appreciation Rights

Herbalife's Chief Commercial Officer, Frank Lamberti, received a grant of 15,182 Stock Appreciation Rights under the company's 2023 Stock Incentive Plan.

Summary

• Frank Lamberti, Chief Commercial Officer of Herbalife Ltd. (HLF), was granted 15,182 Stock Appreciation Rights (SARs).
• The SARs were granted on November 14, 2025, under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan.
• Each SAR has an exercise price of $9.23.
• The SARs will vest in one-third increments on November 14, 2026, November 14, 2027, and November 14, 2028, contingent on continued service.
• The expiration date for these SARs is November 14, 2035.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation grant, which is a neutral to slightly positive event as it aligns management incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The grant of Stock Appreciation Rights aligns the Chief Commercial Officer's financial interests with those of shareholders, incentivizing long-term company performance.
• Equity-based compensation is a standard practice to attract and retain key executives.

Negatives

• No direct negatives are identified in this routine compensation filing.

Risks

• The value of the Stock Appreciation Rights is subject to the future market price fluctuations of Herbalife Ltd. common stock.
• The vesting of the SARs is contingent on the Chief Commercial Officer's continued service, posing a risk if employment is terminated before vesting dates.

Future Outlook

The grant of long-term equity incentives suggests an expectation of continued service from the Chief Commercial Officer and a focus on driving future shareholder value through stock price appreciation.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

The grant of Stock Appreciation Rights is a common form of equity-based compensation for executives in publicly traded companies across various industries, designed to align management incentives with long-term shareholder value creation.

Comparison to Industry Standards

• Equity compensation, such as SARs, is a standard component of executive remuneration packages across the consumer goods and direct selling industries, comparable to practices at companies like Nu Skin Enterprises or USANA Health Sciences.
• The vesting schedule over multiple years is typical for long-term incentive plans, aiming to retain executives and reward sustained performance.

Stakeholder Impact

• Shareholders: Potentially positive, as executive compensation is tied to stock performance, aligning management's interests with shareholder returns.
• Employees: No direct impact on general employees mentioned.

Next Steps

• The SARs will vest in one-third increments on November 14, 2026, November 14, 2027, and November 14, 2028, subject to continued service.

Key Dates

Keywords

Herbalife, HLF, Stock Appreciation Rights, SARs, Executive Compensation, Insider Transaction, Frank Lamberti, Equity Grant, 2023 Stock Incentive Plan